The Sell Now™ Method: Stop Preparing to Launch and Start Proving You Can Sell

Why most startups fail long before launch — by mistaking activity for proof

Stop preparing to launch. Start proving you can sell.

I know how that sounds to a founder who is eighteen months deep in product development, burning down a regulatory checklist, and counting the weeks until the big reveal. It sounds backwards. It is not. It is the single most important reframe I teach, and after three decades of watching disruptive products succeed and fail, I am convinced of it: most startups do not fail at launch. They fail long before it, by mistaking activity for proof.

The activity feels like progress. The product is getting built. The regulatory path is advancing. The website is being polished. But none of that is evidence that a market exists. And for a disruptive product, the market is the thing most likely to kill you.

If the customer won't buy it, time won't fix it.

You are managing the wrong risk

Look honestly at the risk portfolio of an early-stage disruptive company and the numbers are lopsided: roughly 90% of your risk lives on the market side, and only about 10% on the product side. Yet almost all of the early effort — especially for founders who come out of science, life sciences, and medtech — goes into the 10%. Heads are down on product development and FDA clearance. That is where the team's training, instinct, and comfort live.

You do have to build the thing; you cannot sell a product you have not built. But the over-emphasis on product means the market work gets pushed later and later. And when the company finally goes to sell, it discovers the market is not what it assumed. With a truly disruptive product, that gap between assumption and reality is not a risk. It is a certainty. It will happen 100% of the time.

The math is what makes this urgent. Because so much of your risk is on the market side, every dollar and every week you invest in market work before you commit to a full build returns something like 10x what the same investment returns on the product side. Anything you can do to move the market work earlier, you should.

Selling is the only real proof

There is a ladder of data quality, and most founders never climb past the second rung.

At the bottom is internal market research — reports, TAM slides, your own assessment of the opportunity. It feels rigorous. It is the lowest-integrity data you have.

The next rung up is customer discovery: actually going out, interviewing people, asking what problems they have, how they solve them today, what it costs them. When teams make this jump, the quality of their data leaps exponentially. I lead I-Corps for UNC and have taught customer discovery for years — it genuinely changes companies. But here is the uncomfortable truth: it is still just opinions. People will talk about your product all day. Talking is nice to know. It is not need to know.

The top rung — the only rung that gives you real market data — is selling. The moment you ask someone to give you a purchase order, you are in a completely different game. The real market data lives in what people are willing to pay you. When you go from interviewing customers to actually asking them to pay, you get that same exponential leap in data quality all over again. Until you have asked for the money, you do not actually know.

This is also why the conventional Build → Launch → Sell sequence falls apart for disruptive products. If you sell last, you uncover your false assumptions and broken hypotheses last — when they are most expensive to fix. The lean founder in you should hate this: you have over-built before validating that the pieces even work.

What the Sell Now™ method actually is

The Sell Now™ method is discovery selling pushed as early in the company and product lifecycle as it can possibly go. The question I make every founder answer is simple: what is the earliest possible moment we can start selling? For nearly every product, the honest answer is far, far earlier than the team is comfortable with.

Discovery selling is exactly what it sounds like. You are not pitching vaporware. You are putting a real offer in front of a real buyer and learning the truth: Here is what I have, here is what it costs, do you want to buy it — and if not, why not? The "no" is as valuable as the "yes," because both are data.

And to be clear about the goal: the goal is not revenue. The goal is to discover a repeatable sales process. Revenue is simply the evidence that you are moving in the right direction — or the evidence that you need to change, adjust, and pivot. If you cannot close, that is signal, not failure.

Selling early is not a confidence problem

The resistance to this is almost always emotional. I don't want to go to market until it works. If I go out too early, people will think the product is bad — they'll think I'm bad. I understand the instinct. But clinging to "wait until it's ready" creates a serious, compounding risk, and it misreads who you are selling to.

At this stage you are only selling to innovators and early adopters — and a true innovator with a must-solve problem wants their hands on the solution as early as humanly possible. If you are genuinely solving a must-solve problem, waiting actually does the market a disservice. You are withholding something your earliest customers are desperate to use. The early majority — the people who need all the proof before they buy — will not opt into an early sale, and that is exactly as it should be.

The discipline is managing expectations, and doing it through what I call ethical pre-selling. This is not a hustle and it is not pressure. It is transparency. I actually build a test into the early sales process: a gentle push-away. Once a prospect shows interest, I tell them the truth — "This is early, it's not ready for prime time, and working with us means going through a learning process together. If you're not ready for that, you should wait for the commercial product." Then I watch what they do. A true innovator pushes back and pulls me in. An early-majority buyer takes the exit.

I do that on purpose, because I do not want the early majority anywhere near my early customer sites — I don't even want them in my pipeline. When you put a disruptive product in a customer's hands for the first time, the customer is learning how to use it and your company is learning how the customer learns to use it. Early-majority buyers will not endure that. Innovators will partner with you through it.

Why your VP of Sales can hurt you right now

This is also why, early on, it is sometimes better not to work with professional salespeople. A great professional sales organization is trained to do one thing extraordinarily well: execute a repeatable process, in order, at scale, and make money. That is their craft. But a disruptive product has no repeatable sales motion yet — discovering it is the entire point of Sell Now.

Hand a disruptive product to a professional sales team before that motion exists and you have prematurely scaled. You have taken an already-risky situation and multiplied the risk: burn, G&A, stress, frustration, cultural damage — and a team set up to feel like it is failing through no fault of its own. The pros come in after you have discovered the repeatable motion. That is when their skills finally have something to execute against.

The proof: Diagnostic Biochips

This is not theory. Diagnostic Biochips makes tools used in neuroscience and drug-discovery research — a disruptive, non-regulated technology in a market that barely existed commercially. Brian Jamison brought me in 18 to 24 months ago with a deceptively simple goal: go from one big pharma client to three or four. The one client was Merck.

We started where I always start — discovery. We went to see whether the Lillys, GSKs, Pfizers, Amgens, and Regenerons of the world were doing research in this science and would buy. What we learned early was decisive: Merck was a true innovator, and there really were no other early adopters in big pharma. The science and the technology were simply too early. Critically, this was discovery selling, not just discovery — if any of those conversations had started pulling us toward a deal, we would have let them. They didn't.

So we pivoted and went hunting for the real market entry point. We found it in translational research centers — some academic, some non-profit, some private like the Scripps institutions of the world. They had a different risk profile and a different agenda: discovery-oriented, translational, willing to take a chance on something early. We landed about ten early pilot sites — and then deliberately shifted those engagements from free to paid. (I don't do free pilots, ever. There is always a give and take.) Three or four converted into paying customers. And with paying customers, we were finally building a repeatable sales process: we knew our early adopter, we knew the problem we solved, we knew where buyers sat in the adoption cycle, and we knew how to message to them.

On the strength of that, we made a call: pre-launch at the Society for Neuroscience meeting in November — even though the commercial-ready product wouldn't exist until late Q1 or early Q2. Six months out, we ran language-market fit: more discovery with current clients to learn the exact language the market responds to, then testing messaging and outreach right up to the conference.

The result: 180 marketing-qualified leads out of that single meeting, an internal team now working those leads, five or six clients plus the original Merck relationship, and roughly $2.5 million in revenue over eighteen months — all generated before the commercial product shipped. Post-conference, we have already closed two more.

The two upsides that actually matter

Most people assume the payoff of Sell Now is the revenue. It isn't.

The first real upside is market intelligence — the kind you can only get by actually selling. Who buys, and for what reasons. That sales-level data de-risks the entire market side of the business in a way no report or interview ever could.

The second is what happens when you walk into an investor meeting. With Diagnostic Biochips, we are not trying to convince anyone that a market exists. We are showing them. Investors fund evidence, not optimism — and far too often they pour money into a "repeatable sales process" that was never actually discovered, which is even worse than over-building, because now you have scaled a sales team to chase customers you cannot yet name.

That is the epidemic. The two premature-scaling mistakes that kill companies are scaling product development before you have proof, and scaling sales and marketing before you have a repeatable motion. We know better. We just don't behave accordingly.

The Takeaway

If you are at any stage of building a company — even the concept stage — and you have not yet asked yourself what you could sell today, and then run the discovery-selling process against that answer, you are already behind.

People will object: "But I don't have a product." That misunderstands what customers buy. They are not buying your product. They are buying a solution to a very specific, painful problem. If they will not pay to solve that problem today, no amount of time is going to change their mind.

That is the whole discipline in one line.

If they won't buy now, time won't fix it.

This article is part of the Sell Now Lab — frameworks and field notes on selling before you launch. Learn more at viaverus.com.